ArticleMolecular therapy. Oncology2026
Oncolytic virus-delivered GSDME: Unlocking pyroptosis to improve dendritic cell function and amplify cytotoxic T cell response.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic virotherapy is a promising strategy for advanced cancers, but clinical success remains limited. Combining oncolytic viruses with immunogenic cell death modalities offers a potential solution. Pyroptosis, an inflammatory form of programmed cell death mediated by gasdermin proteins, amplifies anti-tumor immune responses through the release of damage-associated molecular patterns. Gasdermin E can switch apoptosis to pyroptosis upon caspase-3 cleavage, but its therapeutic potential is limited due to silenced expression in tumors. Here, we engineered the chimeric Vesicular stomatitis virus (VSV)-GP to express full-length GSDME, enabling pyroptosis induction in GSDME-deficient tumors. VSV-GP-GSDME efficiently delivered GSDME to tumor cells, leading to caspase-3-dependent pyroptotic cell death while retaining replication kinetics and achieving higher therapeutic potency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.